Vietnam Anti-Rheumatic Drug Market - Strategic Insights and Forecasts (2026-2031)

Vietnam Anti-Rheumatic Drug Market is projected to register a strong CAGR during the forecast period (2026-2031).

The Vietnamese anti-rheumatic drug market is currently experiencing a structural reset as a rapidly aging population, with 100% insurance coverage proposed for those over 75 starting in 2026, forces a surge in chronic disease management. Healthcare providers are responding to this demographic pressure by enlisting advanced DMARDs and biosimilars, which are successfully lowering the cost of long-term therapy for rheumatoid arthritis and lupus. This transition is becoming critical as the Revised Pharmacy Law 2024 is currently shortening registration timelines for changes not affecting quality from 3 months to 20 days, currently accelerating patient access to updated formulations. Regulatory influence is expanding through new e-commerce drug business methods, which are currently enabling pharmacy chains to rotate drugs and medicinal ingredients more efficiently across digital platforms. Consequently, the industry is reaching a structural outcome where local manufacturers like Traphaco and DHG Pharma are successfully enlisting EU-GMP upgrades to secure dominant positions in the hospital (EtC) procurement channel.

Market Dynamics

Drivers

• Accelerated Digital Transformation: New 2025 regulations are successfully enlisting e-commerce drug business models, currently allowing pharmacy chains to operate with uniform quality management systems.

• Aging Demographic Pressure: The rising prevalence of musculoskeletal disorders among the elderly is currently forcing the government to plan free annual health checks for all citizens starting in 2026.

• Technology Transfer Incentives: The government is currently enlisting preferential policies for "technology transfer" drugs, encouraging multinational firms to localize the production of advanced anti-rheumatic molecules.

• Public Health Modernization: Vietnam is currently enlisting sweeping reforms in preventive care, which is successfully increasing the early diagnosis of chronic inflammatory diseases.

Restraints and Opportunities

• Strict E-commerce Controls: Wholesaling of controlled drugs via e-commerce remains prohibited, currently constraining the digital supply chain for certain potent pain management therapies.

• Price Management Rigidity: New price announcement requirements for prescription drugs are currently forcing wholesalers to ensure that intermediate markups do not exceed publicly declared limits.

• Biosimilar Localization (Opportunity): The revised law is currently enlisting incentives for domestically produced biopharmaceuticals, providing a clear path for local firms to launch biosimilar TNF-inhibitors.

• Pharmacy Chain Expansion (Opportunity): The legalization of drug rotation within pharmacy chains is currently creating opportunities for high-volume distribution of OTC anti-rheumatic topical treatments.

Supply Chain Analysis

The Vietnamese pharmaceutical supply chain is currently transitioning from a "fragmented distribution" model to a "modernized pharmacy chain" structure to meet digital transformation goals. Distributors are successfully enlisting the newly granted right to rotate professional pharmaceutical personnel and drug stocks between chain nodes, currently reducing localized stockouts. This evolution is becoming critical as manufacturers like Imexpharm are reaching a structural outcome where record net profits are currently supporting the expansion of high-standard manufacturing lines to reduce reliance on imported specialty medicines.

Government Regulations

Key Developments

• DHG Pharma Board Restructuring (December 2025): The board appointed Mr. Toshifumi Kojima as Acting General Director (effective Jan 2026), currently enlisting his performance to guide the firm's 2026 orientation.

• Traphaco CEO Transition (November 2025): Traphaco appointed Ms. Dao Thuy Ha as CEO for the 2021–2026 term, currently enlisting her leadership to target double-digit growth and EU-GMP factory completion by 2026.

Market Segmentation

By Type of Disease

Osteoarthritis and Rheumatoid Arthritis currently anchor the market, as the government is successfully enlisting free annual screenings to identify these conditions in early stages. Gout management is currently witnessing a transition toward modern pharmaceuticals as rising disposable incomes force a shift in lifestyle and diet-related disease patterns. This movement is resulting in an outcome where specialized Lupus treatments are reaching a structural reliance on biopharmaceuticals, currently supported by streamlined registration for innovative molecules.

By Type of Molecule

Traditional Pharmaceuticals currently dominate the market, but manufacturers are successfully enlisting technology-transfer contracts to produce high-quality generics locally. Biopharmaceuticals are currently witnessing the fastest demand shift as the Revised Pharmacy Law 2024 is currently providing a "strong impetus" for modern biological drug development. Consequently, the segment is reaching a structural outcome where local EU-GMP factories are becoming the mechanical necessity for competing in the high-value biological tender market.

By Sales Channel

The Prescription (EtC) channel currently accounts for the majority of total drugs circulated, as the government is successfully enlisting stricter wholesale price management to control hospital procurement costs. Over the Counter (OTC) sales are currently witnessing an expansion through e-commerce, as pharmacy chains are successfully enlisting "online" models to improve patient access to non-controlled analgesics. This shift is forcing an outcome where retail pharmacies must now adopt uniform quality systems to maintain their eligibility for chain operations.

List of Companies

• Pfizer Inc.

• AbbVie Inc.

• F. Hoffmann-La Roche Ltd

• DHG Pharma

• Sun Pharmaceuticals Ltd.

• Traphaco Joint Stock Company

• Imexpharm Corporation

• Domesco Medical Import-Export Joint Stock Corporation

• Binh Dinh Pharmaceutical & Medical Equipment Joint Stock Company (Bidiphar)

• Ha Tay Pharmaceutical Joint Stock Company (Hataphar)

Company Profiles

• Traphaco Joint Stock Company: Strategically distinct for its "dual-engine" strategy, the company is successfully enlisting the leadership of Ms. Dao Thuy Ha to maintain its herbal medicine lead while accelerating EU-GMP modern medicine production.

• DHG Pharma: Notable for its Japanese partnership (Taisho), the company is currently enlisting international governance standards to deliver 12.8% pre-tax profit growth, exceeding its 2025 fiscal targets.

• Imexpharm Corporation: Distinguished by its high-quality focus, the company is successfully enlisting record net profits (up 9% in 2025) to support its fourth consecutive year of sustainable growth in the modern medicine sector.

Analyst View

The Vietnamese anti-rheumatic drug market is entering a "Regulatory-Led Expansion" phase. Success for participants now depends on successfully enlisting EU-GMP certification and technology-transfer partnerships to satisfy 2026 reimbursement expansions and navigate the shortened 9-month registration window for innovative treatments.

Vietnam Anti-Rheumatic Drug Market Scope: